| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/23/2006 | CA2122270C Tri-substituted tetrahydrofuran antifungals |
| 05/23/2006 | CA2087591C Pyrimidine-3-oxide used for reducing hair loss; topical compositions used therefor |
| 05/18/2006 | WO2006053315A2 Methods and compositions for treating cellular proliferative diseases |
| 05/18/2006 | WO2006053255A2 Novel betulin derivatives, preparation thereof and use thereof |
| 05/18/2006 | WO2006053252A2 Methods of treating hematological malignancies with nucleoside analog drugs |
| 05/18/2006 | WO2006053227A2 Il-12 modulatory compounds |
| 05/18/2006 | WO2006053186A2 Method for treatment of movement disorders |
| 05/18/2006 | WO2006053184A2 Methods for treating or preventing a vascular disease |
| 05/18/2006 | WO2006053172A2 The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases |
| 05/18/2006 | WO2006053170A1 Sugars and/or sugar alcohols for inhibiting and/or treating vaginal infection |
| 05/18/2006 | WO2006053166A1 8h-imidazo[4,5-d]thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| 05/18/2006 | WO2006053162A1 Ptpase inhibitors and t-cell activators for treating cancer |
| 05/18/2006 | WO2006053161A1 Use ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure |
| 05/18/2006 | WO2006053160A2 Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases |
| 05/18/2006 | WO2006053159A2 Medical device for delivering biologically active material |
| 05/18/2006 | WO2006053121A2 Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
| 05/18/2006 | WO2006053120A1 IMIDAZO-FUSED THIAZOLO[4,5-b]PYRIDINE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME |
| 05/18/2006 | WO2006053112A1 Process for preparing trisubstituted pyrimidine compounds |
| 05/18/2006 | WO2006053109A1 Heteroaryl compounds |
| 05/18/2006 | WO2006053082A2 Hydroxybenzoate salts of metanicotine compounds |
| 05/18/2006 | WO2006053067A2 Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
| 05/18/2006 | WO2006053049A2 Herbal composition phy906 and its use in chemotherapy |
| 05/18/2006 | WO2006053043A2 Methods of treating diabetes mellitus |
| 05/18/2006 | WO2006053039A2 Hydroxybenzoate salts of metanicotine compounds |
| 05/18/2006 | WO2006053037A2 A new dosing regimen for ion channel modulating compounds for treating acute atrial fibrillation in a human |
| 05/18/2006 | WO2006053024A2 Lactam compounds and their use as pharmaceuticals |
| 05/18/2006 | WO2006053015A2 Composition and method for increasing apoptosis in cancer cells |
| 05/18/2006 | WO2006053012A2 Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria |
| 05/18/2006 | WO2006052976A2 Improved dosing regimen of temozolomide for treating cancer based on the patient’s mgmt level |
| 05/18/2006 | WO2006052962A2 Bicyclic triazole a4 integrin inhibitors |
| 05/18/2006 | WO2006052950A1 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses |
| 05/18/2006 | WO2006052936A2 Compounds and compositions as protein kinase inhibitors |
| 05/18/2006 | WO2006052930A1 Antimicrobial 2-deoxystreptamine compounds |
| 05/18/2006 | WO2006052922A2 Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds |
| 05/18/2006 | WO2006052921A2 Cyclodextrin solubilizers for liquid and semi-solid formulations |
| 05/18/2006 | WO2006052916A2 Histone deacetylase inhibitors |
| 05/18/2006 | WO2006052913A1 PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES |
| 05/18/2006 | WO2006052906A2 Synthesis of cardiolipin analogues and uses thereof |
| 05/18/2006 | WO2006052899A2 Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders |
| 05/18/2006 | WO2006052889A2 Quinolinone-carboxamide compounds |
| 05/18/2006 | WO2006052887A1 Formulations of [1,4]diazepino[6,7,1-ij]quinoline derivatives |
| 05/18/2006 | WO2006052886A1 Metabolites of certain [1,4]diazepino[6,7,1-ij]quinoline derivatives and methods of preparation and use thereof |
| 05/18/2006 | WO2006052880A2 Synergistic effects of combined administration of mirtazapine and a stimulant compound |
| 05/18/2006 | WO2006052860A2 Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation |
| 05/18/2006 | WO2006052856A1 System and method of treatment with nizatidine |
| 05/18/2006 | WO2006052850A2 Motexafin lutetium phototherapy with low fluences for treating vascular inflammation |
| 05/18/2006 | WO2006052844A2 Tolerogenic vaccine and method |
| 05/18/2006 | WO2006052810A2 Combination of a src kinase inhibitor and a bcr-abl inhibitor for the treatment of proliferative diseases |
| 05/18/2006 | WO2006052767A2 Compositions and methods for stabilizing liposomal camptothecin formulations |
| 05/18/2006 | WO2006052722A1 Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof |
| 05/18/2006 | WO2006052718A2 Farnesyltransferase inhibitors for treating sepsis |
| 05/18/2006 | WO2006052712A1 Nanoparticulate compositions of tubulin inhibitor |
| 05/18/2006 | WO2006052710A1 4-hydroxybenzomorphans |
| 05/18/2006 | WO2006052668A2 Induction of antigen specific immunologic tolerance |
| 05/18/2006 | WO2006052640A1 5-ht4 receptor agonist compounds |
| 05/18/2006 | WO2006052630A1 Therapeutic substituted piperidone compounds |
| 05/18/2006 | WO2006052626A2 Dopamine 3 receptor agonist and antagonist treatment of gastrointestinal motility disorders |
| 05/18/2006 | WO2006052569A1 Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists |
| 05/18/2006 | WO2006052568A2 Tgf-beta inhibitors |
| 05/18/2006 | WO2006052555A2 Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| 05/18/2006 | WO2006052546A2 Pyrazolylmethyl heteroaryl derivatives |
| 05/18/2006 | WO2006052542A2 Arylalkyl ureas as cb1 antagonists |
| 05/18/2006 | WO2006052515A1 Cyanoacrylate monomer formulation containing diiodomethyl-p-tolylsulfone and hydroxydiphenyl ether |
| 05/18/2006 | WO2006052499A1 Capreomycin derivatives and their use as antibacterials |
| 05/18/2006 | WO2006052461A2 Novel formulations of eprosartan with enhanced bioavailability |
| 05/18/2006 | WO2006052454A1 Propranolol formulations |
| 05/18/2006 | WO2006052405A1 Propranolol formulations |
| 05/18/2006 | WO2006052378A1 Constrained compounds as cgrp-receptor antagonists |
| 05/18/2006 | WO2006052264A2 Synthesis, characterization and biological action of optically active isomers of floxacins |
| 05/18/2006 | WO2006052190A1 Indazole sulphonamide derivatives |
| 05/18/2006 | WO2006052189A1 Nitro indazole derivatives |
| 05/18/2006 | WO2006052150A1 Mussel extract composition with enhanced anti-inflammatory activity |
| 05/18/2006 | WO2006052026A1 Acid salt of benzimidazole derivative and crystal thereof |
| 05/18/2006 | WO2006052018A1 Aqueous ophthalmic suspension of crystalline rebamipide |
| 05/18/2006 | WO2006052013A1 Thienopyrrole compounds and utilization thereof as hcv polymerase inhibitor |
| 05/18/2006 | WO2006052007A1 Glycemic controlling agent |
| 05/18/2006 | WO2006051997A1 Cystein dioxygenase inducer |
| 05/18/2006 | WO2006051987A1 Novel drug for inhibiting estrogen-dependent diseases, prostaglandin d (pgd)-dependent gynecological diseases, immunological diseases, cancer and angiogenesis |
| 05/18/2006 | WO2006051980A1 Packed beverage for lipid combustion promotion |
| 05/18/2006 | WO2006051951A1 REMEDY FOR DIABETES CONTAINING Cdk5 INHIBITOR |
| 05/18/2006 | WO2006051937A1 Five-membered heterocyclic derivatives |
| 05/18/2006 | WO2006051851A1 2,3,4,5-tetrahydro-1h-1,5-benzodiazepine derivative and medicinal composition |
| 05/18/2006 | WO2006051826A1 Nitrogenous heterocyclic compound and pharmaceutical use thereof |
| 05/18/2006 | WO2006051819A1 Drug for external use and adhesive patch |
| 05/18/2006 | WO2006051818A1 Drug for external use and adhesive patch |
| 05/18/2006 | WO2006051808A1 Hsp90 FAMILY PROTEIN INHIBITORS |
| 05/18/2006 | WO2006051797A1 Therapeutic agent for interstitial cystitis |
| 05/18/2006 | WO2006051773A1 Agent for recovery from cerebral fatigue |
| 05/18/2006 | WO2006051757A1 Remedy or preventive for ischemic cardiac disease or ischemic cardiac myopathy |
| 05/18/2006 | WO2006051704A1 Imine compound |
| 05/18/2006 | WO2006051662A1 Thiazole derivative |
| 05/18/2006 | WO2006051648A1 Remedy for angiospasm accompanying subarachnoid hemorrhage contianing thrombin receptor antagonist as the active ingredient |
| 05/18/2006 | WO2006051549A2 Combination therapy associating preferably a ceramide with a cytotoxic drug |
| 05/18/2006 | WO2006051502A2 Sulfamides as endothelin receptor antagonists for the treatment of cardiovascular diseases |
| 05/18/2006 | WO2006051489A1 Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases |
| 05/18/2006 | WO2006051477A2 Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha |
| 05/18/2006 | WO2006051476A1 Tricyclic guanidine derivatives as sodium-proton exchange inhibitors |
| 05/18/2006 | WO2006051423A1 Compounds which inhibits protein prenylation e.g. geranylgeranyltransferase or farnesyltransferase inhibitors for treating parkinson’s disease |
| 05/18/2006 | WO2006051413A1 Azabenoxazoles for the treatment of cns disorders |
| 05/18/2006 | WO2006051410A1 Azabenzoxazoles for the treatment of cns disorders |